Clinical Trial Update: A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) [Phase 3]

View source ↗

Summary

Phase 3 trial BRAVURA evaluating duvelisib with rituximab and bendamustine versus placebo in indolent non-Hodgkin lymphoma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Indolent Non-hodgkin Lymphoma
• Marginal Zone Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Duvelisib (duvelisib)
• Rituximab (rituximab)

Snippet

Sponsor: SecuraBio | Conditions: Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma | Phase 3 | Status: WITHDRAWN